hCD1a-CAR T

DRUG2 trials

Sponsors

Onechain Immunotherapeutics S.L.

Conditions

T-cell Acute Lymphoblastic LeukemiaT-cell acute lymphoblastic Lymphoma

Phase 1

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

RecruitingCTIS2024-514591-40-00

Onechain Immunotherapeutics S.L.T-cell Acute Lymphoblastic Leukemia, T-cell acute lymphoblastic Lymphoma

Start: 2023-01-31Target: 20Updated: 2025-07-24

Phase 3

Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.

Not yet recruitingCTIS2024-516617-20-00

Onechain Immunotherapeutics S.L.T-cell Acute Lymphoblastic Leukemia, T-cell acute lymphoblastic Lymphoma

Target: 20Updated: 2025-04-11